HVTN 130/ HPTN 089
WHV 138
IAVI G001
HVTN 908
IAVI W001
HVTN 302
RV 546
Research Fundamentals: An HIV Vaccine — What’s the challenge and what’s the science?
Some vaccines are easier to develop than others. COVID-19 vaccines were developed with unprecedented speed, taking a matter of months to become available. A measles vaccine took about 10 years to develop. But the field’s been working on an HIV vaccine for 40 years.
In this episode, AVAC’s Jeanne Baron and co-host immunologist Katharine Kripke of AVENIR Health explore why HIV is different with two experts on vaccine research: Caltech’s Pamela Bjorkman and IAVI’s Vincent Kioi.
Learn how HIV has evolved like no other virus today to escape detection by the immune system. Learn why the right target on HIV is so hard to reach and how scientists are tackling it all.
Previous Research Fundamentals
More Vaccine Resources
Time to Develop a Vaccine
We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward. This graphic is excerpted from Vaccines by the Numbers: Trials, discoveries, money and more.
Phase 1 mRNA HIV Vaccine Trials
A breakdown of current HIV mRNA trials and a primer on the basics of mRNA technology.